Latest Advances

  • Condition: Cryopyrin-Associated Periodic Syndrome (CAPS), Hyperimmunoglobulin D Syndrome (HIDS), and Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)
  • Journal: RMD open
  • Treatment Used: Current Therapies
  • Number of Patients: 0
  • Published —
This review of the literature examined the treatment outcomes of current therapies for rare auto-inflammatory conditions, such as cryopyrin-associated periodic fever syndromes (CAPS), hyperimmunoglobulin Dsyndrome (HIDS)/mevalonate kinase deficiency (MKD) and tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
  • Condition: Monogenic Autoinflammatory Diseases and PFAPA Syndrome
  • Journal: Frontiers in immunology
  • Treatment Used: anti-IL-1 agents and other biologic drugs
  • Number of Patients: 0
  • Published —
This review analyzed the treatment of the most frequent monogenic autoinflammatory diseases.
  • Condition: Pediatric Rheumatic Diseases
  • Journal: The Turkish journal of pediatrics
  • Treatment Used: Canakinumab
  • Number of Patients: 29
  • Published —
In this study, researchers evaluated the outcomes of using canakinumab for the treatment of pediatric rheumatic diseases.
  • Condition: Cryopyrin-Associated Periodic Syndrome (CAPS)
  • Journal: British journal of nursing (Mark Allen Publishing)
  • Treatment Used: Biological Treatments Targeting Interleukin 1 (IL-1)
  • Number of Patients: 0
  • Published —
This article discusses cryopyrin-associated periodic syndrome (CAPS), a group of rare hereditary auto-inflammatory diseases characterized by recurrent flares of mild to severe systemic inflammation and fever, and its treatment.
  • Condition: Children with cryopyrin-associated periodic syndrome
  • Journal: Pediatric rheumatology online journal
  • Treatment Used: Canakinumab
  • Number of Patients: 20
  • Published —
The study researched the safety and effectiveness of canakinumab for children with cryopyrin-associated periodic syndrome.
  • Condition: Cryopyrin-associated Periodic Syndrome
  • Journal: Arthritis & rheumatology (Hoboken, N.J.)
  • Treatment Used: canakinumab
  • Number of Patients: 17
  • Published —
The purpose of the study was to assess the long-term efficacy and safety of canakinumab and the response to vaccination in children ages less than 5 with cryopyrin-associated periodic syndrome.
  • Condition: Children With Periodic Fever Syndromes
  • Journal: Clinical pharmacology and therapeutics
  • Treatment Used: Canakinumab
  • Number of Patients: 0
  • Published —
The study researched the effects of Canakinumab for children with periodic fever syndromes.
Showing 1-7 of 7